论文部分内容阅读
目的观察冻干重组人脑利钠肽治疗慢性充血性心力衰竭的临床疗效。方法 80例慢性充血性心力衰竭患者随机分为新活素组40例和对照组40例。两组患者均给予标准的抗心力衰竭治疗,新活素组加用冻干重组人脑利钠肽,首次负荷剂量为1.5μg/kg静脉注射,然后按0.0075μg/(kg·min)剂量持续静脉泵入,连续用药72h。观察患者治疗前及治疗后1周的临床症状、血浆中NT-proBNP的浓度及左室射血分数(LVEF)等情况。结果新活素组的治疗总有效率显著优于对照组(P<0.01)。新活素组治疗1周后各项指标的变化较对照组明显改善(P<0.05)。结论冻干重组人脑利钠肽治疗慢性充血性心力衰竭,可以降低血浆中NT-proBNP的浓度,显著改善患者的临床症状和心功能。
Objective To observe the clinical efficacy of lyophilized recombinant human brain natriuretic peptide in the treatment of chronic congestive heart failure. Methods Eighty patients with chronic congestive heart failure were randomly divided into the new active group 40 cases and the control group 40 cases. Patients in both groups were given standard anti-heart failure treatment. Xin-Su group was given intravenous injection of freeze-dried recombinant human brain natriuretic peptide at a first loading dose of 1.5 μg / kg and then at a dosage of 0.0075 μg / (kg · min) Venous pump, continuous medication 72h. The clinical symptoms, the concentration of NT-proBNP in plasma and the left ventricular ejection fraction (LVEF) before and after treatment were observed. Results The total effective rate of new activin group was significantly better than that of control group (P <0.01). After 1 week treatment, the changes of various indexes in the new activin group were significantly improved compared with the control group (P <0.05). Conclusion The use of lyophilized recombinant human brain natriuretic peptide in the treatment of chronic congestive heart failure can reduce the concentration of NT-proBNP in plasma and significantly improve the clinical symptoms and cardiac function.